Apixaban vs Aspirin According to CHA2DS2-VASc Score in Subclinical Atrial Fibrillation

One in 4 patients in ARTESiA with subclinical atrial fibrillation had a CHA₂DS₂-VASc score >4 and a stroke/SE risk of 2.2% per year. For these patients, the benefits of treatment with apixaban in preventing stroke/SE are greater than the risks. The opposite is true for patients with CHA₂DS₂-VASc score <4. A substantial intermediate group (CHA₂DS₂-VASc =4) exists in which patient preferences will inform treatment decisions. (Apixaban for the Reduction of Thrombo-Embolism in Patients With Device-Detected Sub-Clinical Atrial Fibrillation; NCT01938248).